GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Forward PE Ratio

Relay Therapeutics (Relay Therapeutics) Forward PE Ratio : 0.00 (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Forward PE Ratio?

Relay Therapeutics's Forward PE Ratio for today is 0.00.

Relay Therapeutics's PE Ratio without NRI for today is 0.00.

Relay Therapeutics's PE Ratio for today is 0.00.


Relay Therapeutics Forward PE Ratio Historical Data

The historical data trend for Relay Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Forward PE Ratio Chart

Relay Therapeutics Annual Data
Trend
Forward PE Ratio

Relay Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Relay Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Relay Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relay Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Relay Therapeutics's Forward PE Ratio falls into.



Relay Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Relay Therapeutics  (NAS:RLAY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Relay Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Relay Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Relay Therapeutics (Relay Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Executives
Peter Rahmer officer: See remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Thomas Catinazzo officer: Vice President, Finance C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Donald A Bergstrom officer: See Remarks 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams officer: General Counsel 750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel director, officer: President and CEO C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter officer: See Remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan director 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram director 2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd 10 percent owner 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc 10 percent owner 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver director 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518